National Stroke Foundation

Teveten (eprosartan mesylate)

The following drug information is obtained from various newswires, published medical journal articles, and medical conference presentations.

Approval Status:

Approved December 1997

Specific Treatments:


General Information

Teveten was approved for the treatment of hypertension, as either a monotherapy or for use in combination with other antihypertensives.

Mechanism of Action

Teveten is an angiotensin II antagonist.